Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can better heart blood flow predict how far you can walk? new study investigates.

NCT ID NCT07150299

Knowledge-focused Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at 20 people with hypertrophic obstructive cardiomyopathy who are already on optimal medical therapy. Researchers want to see if changes in heart blood flow over one year are linked to changes in how far they can walk in six minutes. Participants will have two heart MRI scans and walking tests as part of their routine care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mavacamten
What this could lead to
If successful, this could help doctors better understand how medication improves blood flow and exercise capacity in people with hypertrophic cardiomyopathy.
What could go wrong
This is a small, early observational study with only 20 participants, so results may not apply to everyone. It looks at correlations, not direct treatment effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with oHCM on maximal tolerated background therapy which will receive mavacamten as add-on

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Willingness to provide written informed consent * Diagnosis of obstructive HCM based on ESC 2023 criteria * Planned CMR with myccardial perfusion for clinical purposes * Receiving guideline-conform OMT * Ability and willingness to undergo follow-up imaging and testing * Written informed consent Exclusion Criteria: * Claustrophobia or other contraindication for CMR imaging * Significant coronary artery disease and/or prior stent implantation or coronary artery bypass graft surgery * History of sudden cardiac arrest or sustained ventricular arrhythmia 12 months prior to screening * Glomerular filtration rate \< 30ml/min/m2 * Significant hepatic impairment defined as 3x upper limit of normal of transaminases, total bilirubin, or alkaline phosphatase; hepatic cirrhosis * Known allergy to contrast agent * Alternative disease causing hypertrophic cardiomyopathy (e.g. cardiac amyloidosis, Morbus Fabry) * Pregnant women (and women with childbearing potential with desire for pregnancy) * Breastfeeding women * Unwillingness to comply with the study protocol and its procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertrophic obstructive cardiomyopathy \(hocm\) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertrophic obstructive cardiomyopathy \(hocm\)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical University of Vienna

    RECRUITING

    Vienna, 2362, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.